Impax Laboratories (IPXL) versus Concordia International (CXRX) Financial Contrast
Impax Laboratories (NASDAQ: IPXL) and Concordia International (NASDAQ:CXRX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, risk, dividends, institutional ownership and profitability.
Volatility and Risk
Impax Laboratories has a beta of 0.94, indicating that its stock price is 6% less volatile than the S&P 500. Comparatively, Concordia International has a beta of 0.85, indicating that its stock price is 15% less volatile than the S&P 500.
This is a summary of current ratings and price targets for Impax Laboratories and Concordia International, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Impax Laboratories currently has a consensus price target of $20.29, suggesting a potential upside of 16.92%. Given Impax Laboratories’ stronger consensus rating and higher probable upside, analysts plainly believe Impax Laboratories is more favorable than Concordia International.
Earnings & Valuation
This table compares Impax Laboratories and Concordia International’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Impax Laboratories||$824.43 million||1.56||-$472.03 million||($6.25)||-2.78|
|Concordia International||$816.16 million||0.05||-$1.32 billion||($35.68)||-0.02|
Impax Laboratories has higher revenue and earnings than Concordia International. Impax Laboratories is trading at a lower price-to-earnings ratio than Concordia International, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
90.5% of Impax Laboratories shares are held by institutional investors. Comparatively, 8.7% of Concordia International shares are held by institutional investors. 3.2% of Impax Laboratories shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
This table compares Impax Laboratories and Concordia International’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Impax Laboratories beats Concordia International on 13 of the 14 factors compared between the two stocks.
About Impax Laboratories
Impax Laboratories, Inc. is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma. The Impax Generics segment is focused on the development, manufacture, sale and distribution of its generic products, which are the pharmaceutical and therapeutic equivalents of brand-name drug products and are marketed under their established drug names. The Impax Specialty Pharma segment is engaged in the promotion, sale and distribution of several branded products, including its branded pharmaceutical product, Rytary, an extended release oral capsule formulation of carbidopa-levodopa for the treatment of Parkinson’s disease, post-encephalitic Parkinsonism and Parkinsonism, and Zomig (zolmitriptan) products, indicated for the treatment of migraine headaches.
About Concordia International
Concordia International Corp, formerly Concordia Healthcare Corp, is a Canada-based pharmaceutical company. The Company, through subsidiaries, owns a portfolio of branded and generic prescription products. Its activities are divided into four segments: Concordia North America, includes sales of pharmaceutical products, such as Donnatal for the treatment of irritable bowel syndrome, Zonegran for the treatment of partial seizures in adults with epilepsy and Nilandron for the treatment of metastatic prostate cancer; Concordia International, includes a portfolio of branded and generic products that are sold to wholesalers, hospitals and pharmacies in over 100 countries, and focuses on acquisition, licensing and development of off-patent prescription medicines; Orphan Drugs, includes Photofrin, which is for the treatment of certain forms of rare cancer, and Corporate cost centre, includes centralized costs incurred by the Company.
Receive News & Ratings for Impax Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Impax Laboratories and related companies with Analyst Ratings Network's FREE daily email newsletter.